Psymberin, a potent sponge-derived cytotoxin from Psammocinia distantly related to the pederin family

Organic Letters

Volumn 6, Issue 12, 2004, Pages 1951-1954

  Cichewicz, Robert H ^a   Valeriote, Frederick A ^b   Crews, Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Josephine Ford Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; PEDERIN; PSYMBERIN; UNCLASSIFIED DRUG;

ARTICLE; CELL FRACTIONATION; DRUG ISOLATION; DRUG POTENCY; DRUG STRUCTURE; NONHUMAN; PSAMMOCINIA; SPONGE (PORIFERA); STEREOCHEMISTRY; STRUCTURE ANALYSIS;

EID: 3042706094     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol049503q     Document Type: Article

References (30)

1. (a) Isolation: Clark, W. D.; Corbett, T.; Valeriote, F.; Crews, P. J. Am. Chem. Soc. 1997, 119, 9285-9286.
2. (b) Synthesis of a diastereomer: Grieco, P. A.; Reilly, M. Tetrahedron Lett. 1998, 39, 8925-8928.
3. (a) Swinholide A was identified by comparison to data in Kobayashi, M.; Tanaka, J.; Katori, T.; Matsuura, M.; Kitagawa, I. Tetrahedron Lett. 1989, 30, 2963-2966.
4. (b) Variabilin was identified by comparison to data in Faulkner, D. J. Tetrahedron Lett. 1973, 39, 3821-3822.
5. (c) Polybrominated phenol ethers were identified by comparison to data in Bowden, B. F.; Towerzey, L.; Junk, P. C. Aust. J. Chem. 2000, 53, 299-301.
6. Salva, J.; Faulkner, D. J. J. Nat. Prod. 1990, 53, 757-760.
7. 3, q).
8. Methylation of 1 was performed as described in Hashimoto, N.; Aoyama, T.; Shioiri, T. Chem. Pharm. Bull. 1981, 29, 1475-1478. Although we originally favored C1 as a possible substructure, we are grateful to an anonymous reviewer who noted the potential of phenols to undergo O-methylation (Toyohiko, A.; Terasawa, S.; Sudo, K.; Shioiri, T. Chem. Pharm. Bull. 1984, 32, 3759-3760.).
9. Methylation of 1 was performed as described in Hashimoto, N.; Aoyama, T.; Shioiri, T. Chem. Pharm. Bull. 1981, 29, 1475-1478. Although we originally favored C1 as a possible substructure, we are grateful to an anonymous reviewer who noted the potential of phenols to undergo O-methylation (Toyohiko, A.; Terasawa, S.; Sudo, K.; Shioiri, T. Chem. Pharm. Bull. 1984, 32, 3759-3760.).
10. Shortly after the completion of this work we learned that iciniastatin A, possessing properties identical to those of psymberin (1) had been disclosed: Pettit, G. R.; Xu, J.-P.; Chapuis, J.-C.; Pettit, R. K.; Tackett, L. P.; Doubek, D. L.; Hooper, J. N. A.; Schmidt, J. M. J. Med. Chem. 2004, 47, 1149-1152. The name has been retained because of its prior incorporation in the research at collaborating institutions.
11. Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. J. Org. Chem. 1999, 64, 866-876.
12. Perry, N. B.; Blunt, J. W.; Munro, M. H. G.; Thompson, A. M. J. Org. Chem. 1990, 55, 223-227.
13. A different 7R* (same as position C-8 in psymberin, 1) configuration was proposed for irciniastatin A (see ref 5).
14. (a) Krohn, K.; Bahramsari, R.; Florke, U.; Ludewig, K.; Kliche-Spory, C.; Michel, A.; Aust, H.-J.; Draeger, S.; Schulz, B.; Antus, S. Phytochemistry 1997, 45, 313-320,
15. (b) Arakawa, H. Bull. Chem. Soc. Jpn. 1968, 41, 2541.
16. (a) Narquizian, R.; Kocienski, P. J. In The Role of Natural Products in Drug Discovery; Mulzer, J., Bohlmann, R., Eds.; Ernst Schering Research Foundation Workshop 32; Springer: New York, 2000; pp 25-56. (b) See also Table S1.
17. (a) Furusaki, A.; Watanabé, T.; Matsumoto, T.; Yanagiya, M. Tetrahedron Lett. 1968, 60, 6301-6304.
18. (b) Kocienski, P.; Narquizian, R.; Raubo, P.; Smith, C.; Farrugia, L. J.; Muir, K.; Boyle, F. T. J. Chem. Soc., Perkin Trans. 1 2000, 2357-2384. (c) See also ref 10.
19. SAR studies have revealed that a 5S,8S absolute configuration is required for the potent cytotoxicity observed for analogous pederin-like compounds (see Figure 1 for numbering and ref 10).
20. (a) All reported members of the pederin family possess optical rotations ranging between [α] = +22 (onnamide F: Vuong, D.; Capon, R. J.; Lacey, E.; Gill, J. H.; Heiland, K.; Friedel, T. J. Nat. Prod. 2001, 64, 640-642) and [α] = +172 (theopederin C: Fusetani, N.; Sugawara, T.; Matsunaga, S. J. Org. Chem. 1992, 57, 3828-3832). (b) See Table S1 for the optical rotations for all pederin metabolites.
21. (a) All reported members of the pederin family possess optical rotations ranging between [α] = +22 (onnamide F: Vuong, D.; Capon, R. J.; Lacey, E.; Gill, J. H.; Heiland, K.; Friedel, T. J. Nat. Prod. 2001, 64, 640-642) and [α] = +172 (theopederin C: Fusetani, N.; Sugawara, T.; Matsunaga, S. J. Org. Chem. 1992, 57, 3828-3832). (b) See Table S1 for the optical rotations for all pederin metabolites.
22. (a) Piel, J. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14002-14007.
23. (b) Piel, J.; Wen, G.; Platzer, M.; Hui, D. ChemBioChem 2004, 5, 93-98.
24. The name psymberin is derived from Psammocinia + symbiont + pederin in view of its relationship to the pederin family.
25. Bioassay procedures are described in Valeriote, F.; Grieshaber, C. K.; Media, J.; Pietraszkewicz, H.; Hoffmann, J.; Pan, M.; McLaughlin, S. J. Exp. Ther. Oncol. 2002, 2, 228-236.
26. (a) Burres, N. S.; Clement, J. J. Cancer Res. 1989, 49, 2935-2940.
27. (b) Kobayashi, J.; Itagaki, F.; Shigemori, H.; Sasaki, T. J. Nat. Prod. 1993, 56, 976-981.
28. (c) West, L. M.; Northcote, P. T.; Hood, K. A.; Miller, J. H.; Page, M. J. J. Nat. Prod. 2000, 63, 707-709.
29. (d) Hood, K. A.; West, L. M.; Northcote, P. T.; Berridge, M. V.; Miller, J. H. Apoptosis 2001, 6, 207-219.
30. (e) Paul, G. K.; Gunasekera, S. P.; Longley, R. E.; Pomponi, S. A. J. Nat. Prod. 2002, 65, 59-61.